2019
DOI: 10.1634/theoncologist.2019-0291
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background Bevacizumab, a VEGF‐A inhibitor, in combination with chemotherapy, has proven to increase progression‐free survival (PFS) and overall survival in multiple lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor angiopoetin‐2 (Ang‐2) is associated with poor prognosis in many cancers, including mCRC. Preclinical models demonstrate improved activity when inhibiting both VEGF‐A and Ang‐2, suggesting that the dual VEGF‐A and Ang‐2 blocker vanucizumab (RO5520985 or RG‐7221) may impr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
17
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(18 citation statements)
references
References 36 publications
1
17
0
Order By: Relevance
“…The affinity of each Fab arm was essentially the same as that of the parental antibody, and the thermal stability was also similar to that of conventional IgG. The bsAb, vanucizumab, in combination with mFOLFOX-6 failed improve the progression-free survival of metastatic colorectal cancer (mCRC) patients relative to the bevacizumab-treated group [58]. A different Ang-2×VEGF CrossMab, faricimab, is being evaluated in a number of phase 3 clinical trials for the treatment of neovascular age-related macular degeneration (nAMD) (NCT03823287 and NCT03823300) and diabetic macular edema (NCT03622580 and NCT03622593).…”
Section: Asymmetric Fc-based Bsabsmentioning
confidence: 90%
“…The affinity of each Fab arm was essentially the same as that of the parental antibody, and the thermal stability was also similar to that of conventional IgG. The bsAb, vanucizumab, in combination with mFOLFOX-6 failed improve the progression-free survival of metastatic colorectal cancer (mCRC) patients relative to the bevacizumab-treated group [58]. A different Ang-2×VEGF CrossMab, faricimab, is being evaluated in a number of phase 3 clinical trials for the treatment of neovascular age-related macular degeneration (nAMD) (NCT03823287 and NCT03823300) and diabetic macular edema (NCT03622580 and NCT03622593).…”
Section: Asymmetric Fc-based Bsabsmentioning
confidence: 90%
“…A phase I study using biweekly administration of vanucizumab in patients with solid tumors confirmed its safety and anti-angiogenesis activities [ 66 ]. Recently, the results of a phase II clinical trial, McCAVE trial, in patients with previously untreated metastatic CRC revealed that angiogenesis inhibition by vanucizumab does not provide additional benefits over bevacizumab for first‐line treatment of metastatic CRC [ 67 ].…”
Section: Monoclonal Antibodiesmentioning
confidence: 99%
“…However, a Phase I clinical trial in patients with platinum‐resistant, recurrent ovarian cancer found that combination treatment with vanucizumab and atezolizumab did not promote antitumor activity better than atezolizumab monotherapy (Oaknin et al, 2017). Moreover, a Phase II clinical trial in patients with metastatic colorectal cancer found that combination treatment with vanucizumab and the chemotherapeutic regimen mFOLFOX‐6 led to reduced progression‐free survival compared to bevacizumab/mFOLFOLX‐6 combination therapy, and also resulted in a higher number of reported adverse effects (Bendell et al, 2020). These results have cast doubt on the clinical future of vanucizumab.…”
Section: Bispecific Antibodies Targeting Cancer Metastasismentioning
confidence: 99%